secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2021-07-19T23:59:59+00:00
Accession:  0000805928-21-000130
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen appoints John H. Johnson to board, effective July 19, 2021
-----------------------------------------------------------------

- Board increased from eight to nine members; Johnson appointed effective July 19, 2021.
- Johnson is CEO of Strongbridge Biopharma with 30+ years of biopharma experience.
- He will serve on the Governance, Nominating and Sustainability Committee and Science and Technology Committee.
- Standard director compensation: quarterly cash retainers ($10K board, $1.25K per committee) and stock option grants.
- Johnson previously held senior roles at Eli Lilly, J&J, ImClone, and Dendreon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592821000130/0000805928-21-000130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592821000130/axgn-20210716.htm
  HTML page:      https://secwatch.observer/filing/0000805928-21-000130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer